The pathophysiology of circulating corticotropin-releasing hormone-binding protein levels in the human.
To establish the factors that modulate circulating CRH-binding protein (CRH-BP) levels, we measured plasma CRH-BP in patients with a variety of endocrine and systemic disorders. CRH-BP was measured by RIA. Young women have higher plasma levels of CRH-BP than young men [females (n = 18), mean +/- SEM...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
1998
|
| _version_ | 1797084799334088704 |
|---|---|
| author | Trainer, P Woods, R Korbonits, M Popovic, V Stewart, P Lowry, P Grossman, AB |
| author_facet | Trainer, P Woods, R Korbonits, M Popovic, V Stewart, P Lowry, P Grossman, AB |
| author_sort | Trainer, P |
| collection | OXFORD |
| description | To establish the factors that modulate circulating CRH-binding protein (CRH-BP) levels, we measured plasma CRH-BP in patients with a variety of endocrine and systemic disorders. CRH-BP was measured by RIA. Young women have higher plasma levels of CRH-BP than young men [females (n = 18), mean +/- SEM, 145 +/- 7; males (n = 20), 99 +/- 6 ng/mL; P < 0.0001], but levels do not fall with the menopause or vary during the menstrual cycle and are unaffected by estrogen replacement therapy. Levels were lower in patients with liver disease than in healthy men (26 +/- 3 vs. 99 +/- 6; P < 0.0001) and were elevated in chronic renal failure compared to those in healthy women (211 +/- 11.2 vs. 145 +/- 7; P < 0.01). Levels were unaffected by fasting in men or women (male fasted, 97 +/- 11; male fed, 97 +/- 8; female fasted, 136 +/- 9; female fed, 152 +/- 10). Dexamethasone treatment lowered CRH-BP in all subjects (129 +/- 8 vs. 111 +/- 9; P < 0.003). Similarly, CRH-BP levels were lower in patients with Cushing's syndrome (all female) than in healthy female controls (median, 82; range, 53-106; vs. median, 142; range, 101-190; P < 0.0001). In Cushing's patients, an i.v. bolus of 100 micrograms human CRH further lowered plasma CRH-BP at 15 min (81 +/- 5 vs. 50 +/- 4; P < 0.0003). Plasma levels of CRH-BP are higher in women than men, but this is unrelated to circulating estrogen levels. The low levels in liver disease and the high levels in renal failure support its hepatic origin and the kidneys as the route of clearance from plasma. The ability of glucocorticoids and exogenous CRH to lower plasma CRH-BP levels and of CRH-BP to modulate the bioactivity of circulating CRH suggest that the protein may be an important regulator of circulating CRH or related ligands. |
| first_indexed | 2024-03-07T02:00:07Z |
| format | Journal article |
| id | oxford-uuid:9d12c8f7-d10c-4f4e-8960-29fa6bb03d97 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T02:00:07Z |
| publishDate | 1998 |
| record_format | dspace |
| spelling | oxford-uuid:9d12c8f7-d10c-4f4e-8960-29fa6bb03d972022-03-27T00:40:21ZThe pathophysiology of circulating corticotropin-releasing hormone-binding protein levels in the human.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:9d12c8f7-d10c-4f4e-8960-29fa6bb03d97EnglishSymplectic Elements at Oxford1998Trainer, PWoods, RKorbonits, MPopovic, VStewart, PLowry, PGrossman, ABTo establish the factors that modulate circulating CRH-binding protein (CRH-BP) levels, we measured plasma CRH-BP in patients with a variety of endocrine and systemic disorders. CRH-BP was measured by RIA. Young women have higher plasma levels of CRH-BP than young men [females (n = 18), mean +/- SEM, 145 +/- 7; males (n = 20), 99 +/- 6 ng/mL; P < 0.0001], but levels do not fall with the menopause or vary during the menstrual cycle and are unaffected by estrogen replacement therapy. Levels were lower in patients with liver disease than in healthy men (26 +/- 3 vs. 99 +/- 6; P < 0.0001) and were elevated in chronic renal failure compared to those in healthy women (211 +/- 11.2 vs. 145 +/- 7; P < 0.01). Levels were unaffected by fasting in men or women (male fasted, 97 +/- 11; male fed, 97 +/- 8; female fasted, 136 +/- 9; female fed, 152 +/- 10). Dexamethasone treatment lowered CRH-BP in all subjects (129 +/- 8 vs. 111 +/- 9; P < 0.003). Similarly, CRH-BP levels were lower in patients with Cushing's syndrome (all female) than in healthy female controls (median, 82; range, 53-106; vs. median, 142; range, 101-190; P < 0.0001). In Cushing's patients, an i.v. bolus of 100 micrograms human CRH further lowered plasma CRH-BP at 15 min (81 +/- 5 vs. 50 +/- 4; P < 0.0003). Plasma levels of CRH-BP are higher in women than men, but this is unrelated to circulating estrogen levels. The low levels in liver disease and the high levels in renal failure support its hepatic origin and the kidneys as the route of clearance from plasma. The ability of glucocorticoids and exogenous CRH to lower plasma CRH-BP levels and of CRH-BP to modulate the bioactivity of circulating CRH suggest that the protein may be an important regulator of circulating CRH or related ligands. |
| spellingShingle | Trainer, P Woods, R Korbonits, M Popovic, V Stewart, P Lowry, P Grossman, AB The pathophysiology of circulating corticotropin-releasing hormone-binding protein levels in the human. |
| title | The pathophysiology of circulating corticotropin-releasing hormone-binding protein levels in the human. |
| title_full | The pathophysiology of circulating corticotropin-releasing hormone-binding protein levels in the human. |
| title_fullStr | The pathophysiology of circulating corticotropin-releasing hormone-binding protein levels in the human. |
| title_full_unstemmed | The pathophysiology of circulating corticotropin-releasing hormone-binding protein levels in the human. |
| title_short | The pathophysiology of circulating corticotropin-releasing hormone-binding protein levels in the human. |
| title_sort | pathophysiology of circulating corticotropin releasing hormone binding protein levels in the human |
| work_keys_str_mv | AT trainerp thepathophysiologyofcirculatingcorticotropinreleasinghormonebindingproteinlevelsinthehuman AT woodsr thepathophysiologyofcirculatingcorticotropinreleasinghormonebindingproteinlevelsinthehuman AT korbonitsm thepathophysiologyofcirculatingcorticotropinreleasinghormonebindingproteinlevelsinthehuman AT popovicv thepathophysiologyofcirculatingcorticotropinreleasinghormonebindingproteinlevelsinthehuman AT stewartp thepathophysiologyofcirculatingcorticotropinreleasinghormonebindingproteinlevelsinthehuman AT lowryp thepathophysiologyofcirculatingcorticotropinreleasinghormonebindingproteinlevelsinthehuman AT grossmanab thepathophysiologyofcirculatingcorticotropinreleasinghormonebindingproteinlevelsinthehuman AT trainerp pathophysiologyofcirculatingcorticotropinreleasinghormonebindingproteinlevelsinthehuman AT woodsr pathophysiologyofcirculatingcorticotropinreleasinghormonebindingproteinlevelsinthehuman AT korbonitsm pathophysiologyofcirculatingcorticotropinreleasinghormonebindingproteinlevelsinthehuman AT popovicv pathophysiologyofcirculatingcorticotropinreleasinghormonebindingproteinlevelsinthehuman AT stewartp pathophysiologyofcirculatingcorticotropinreleasinghormonebindingproteinlevelsinthehuman AT lowryp pathophysiologyofcirculatingcorticotropinreleasinghormonebindingproteinlevelsinthehuman AT grossmanab pathophysiologyofcirculatingcorticotropinreleasinghormonebindingproteinlevelsinthehuman |